Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (282)	10/17/2001 12:50:56 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

here's some insight re. Message Pharmaceuticals.......... Trends Biotechnol 2000 Aug;18(8):349-56 RNA as a drug target: methods for biophysical characterization and screening. Xavier KA, Eder PS, Giordano T. Message Pharmaceuticals, Malvern, PA 19355, USA. xavier@messagepharm.com RNA folds into complex structures that can interact specifically with effector proteins. These interactions are essential for various biological functions. In order to discover small molecules that can affect important RNA-protein complexes, a thorough analysis of the thermodynamics and kinetics of RNA-protein binding is required. This can facilitate the formulation of high-throughput screening strategies and the development of structure-activity relationships for compound leads. In addition to traditional methods, such as filter binding, gel mobility shift assay and various fluorescence techniques, newer methods such as surface plasmon resonance and mass spectrometry are being used for the study of RNA-protein interactions. Eder's last first author publication was from Yale in 1997.